Managing Nonmetastatic Castration-resistant Prostate Cancer

Joaquin Mateo; Karim Fizazi; Silke Gillessen; Axel Heidenreich; Raquel Perez-Lopez; Wim J.G. Oyen; Neal Shore; Matthew Smith; Christopher Sweeney; Bertrand Tombal; Scott A. Tomlins; Johann S. de Bono

doi:10.1016/j.eururo.2018.07.035

Managing Nonmetastatic Castration-resistant Prostate Cancer

Joaquin Mateo, Karim Fizazi, Silke Gillessen, Axel Heidenreich, Raquel Perez-Lopez, Wim J.G. Oyen, Neal Shore, Matthew Smith, Christopher Sweeney, Bertrand Tombal, Scott A. Tomlins, Johann S. de Bono

Research output: Contribution to journal › Review article › peer-review

118 Citations (Scopus)

Abstract

Nonmetastatic castration-resistant prostate cancer is a heterogeneous clinical state defined by rising prostate-specific antigen on androgen deprivation therapy but without imaging evidence of metastatic disease. New systemic therapies prolong time to metastatic disease. More sensitive imaging modalities will likely redefine this state in the near future.

Original language	English
Pages (from-to)	285-293
Number of pages	9
Journal	European Urology
Volume	75
Issue number	2
DOIs	https://doi.org/10.1016/j.eururo.2018.07.035
Publication status	Published - 1 Feb 2019
Externally published	Yes

Keywords

Apalutamide
Castration-resistant prostate cancer
Enzalutamide
Imaging biomarkers
Metastasis-free survival
Nonmetastatic castration-resistant prostate cancer
Prostate-specific antigen doubling time

Access to Document

10.1016/j.eururo.2018.07.035

Cite this

@article{9f0160341b2c4712942ce7249a4c24dd,

title = "Managing Nonmetastatic Castration-resistant Prostate Cancer",

abstract = "Nonmetastatic castration-resistant prostate cancer is a heterogeneous clinical state defined by rising prostate-specific antigen on androgen deprivation therapy but without imaging evidence of metastatic disease. New systemic therapies prolong time to metastatic disease. More sensitive imaging modalities will likely redefine this state in the near future.",

keywords = "Apalutamide, Castration-resistant prostate cancer, Enzalutamide, Imaging biomarkers, Metastasis-free survival, Nonmetastatic castration-resistant prostate cancer, Prostate-specific antigen doubling time",

author = "Joaquin Mateo and Karim Fizazi and Silke Gillessen and Axel Heidenreich and Raquel Perez-Lopez and Oyen, {Wim J.G.} and Neal Shore and Matthew Smith and Christopher Sweeney and Bertrand Tombal and Tomlins, {Scott A.} and {de Bono}, {Johann S.}",

note = "Publisher Copyright: {\textcopyright} 2018 The Authors",

year = "2019",

month = feb,

day = "1",

doi = "10.1016/j.eururo.2018.07.035",

language = "English",

volume = "75",

pages = "285--293",

journal = "European Urology",

issn = "0302-2838",

number = "2",

}

TY - JOUR

T1 - Managing Nonmetastatic Castration-resistant Prostate Cancer

AU - Mateo, Joaquin

AU - Fizazi, Karim

AU - Gillessen, Silke

AU - Heidenreich, Axel

AU - Perez-Lopez, Raquel

AU - Oyen, Wim J.G.

AU - Shore, Neal

AU - Smith, Matthew

AU - Sweeney, Christopher

AU - Tombal, Bertrand

AU - Tomlins, Scott A.

AU - de Bono, Johann S.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Nonmetastatic castration-resistant prostate cancer is a heterogeneous clinical state defined by rising prostate-specific antigen on androgen deprivation therapy but without imaging evidence of metastatic disease. New systemic therapies prolong time to metastatic disease. More sensitive imaging modalities will likely redefine this state in the near future.

AB - Nonmetastatic castration-resistant prostate cancer is a heterogeneous clinical state defined by rising prostate-specific antigen on androgen deprivation therapy but without imaging evidence of metastatic disease. New systemic therapies prolong time to metastatic disease. More sensitive imaging modalities will likely redefine this state in the near future.

KW - Apalutamide

KW - Castration-resistant prostate cancer

KW - Enzalutamide

KW - Imaging biomarkers

KW - Metastasis-free survival

KW - Nonmetastatic castration-resistant prostate cancer

KW - Prostate-specific antigen doubling time

UR - http://www.scopus.com/inward/record.url?scp=85051557516&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2018.07.035

DO - 10.1016/j.eururo.2018.07.035

M3 - Review article

C2 - 30119985

AN - SCOPUS:85051557516

SN - 0302-2838

VL - 75

SP - 285

EP - 293

JO - European Urology

JF - European Urology

IS - 2

ER -

Managing Nonmetastatic Castration-resistant Prostate Cancer

Abstract

Keywords

Access to Document

Other files and links

Cite this